medigraphic.com

2019, Number 4

<< Back Next >>

Enf Infec Microbiol 2019; 39 (4)

Actualities in breast implants infections

Martínez HL, López EC

Language: Spanish
References: 44
Page: 134-139
PDF size: 244.46 Kb.


ABSTRACT

Breast implant surgery or mammaplasty is the most frequent cosmetic surgery performed. Surgical site infection (ssi) is the leading complication with a reported incidence of 1.1 to 2.5% in cosmetic surgery procedures, rising up to 35% in breast reconstruction surgeries. Early infections are related to gram positive bacteria such as coagulase-negative staphylococci, Staphylococcus aureus and Streptococcus. Late infections are the result from secondary bacteremia or an invasive procedure, and can be caused by both gram positive and negative bacteria and rarely by mycobacteria and fungi. The risk factors are surgical technique and the underlying condition of the patient. Potential sources of infection include the patient skin, breast ducts, the surgical environment and contaminated implants. An empirical antibiotic regimen should include coverage for S. aureus, coagulase-negative staphylococci and gram negative bacteria. Removal of the implant is frequently required but salvage can be attempted in carefully selected situations.


REFERENCES

  1. Olsen, M.A., Nickel, K.B., Fox, I.K., Margenthaler, J.A., Ball, K.E., Mines, D. et al., “Incidence of surgical site infection following mastectomy with and without immediate reconstruction using private insurer claims data”, Infect Control Hosp Epidemiol, 2015, 36 (8): 907-914.

  2. Rubino, C., Brongo, S., Pagliara, D., Cuomo, R., Abbinante, G., Campitiello, N. et al., “Infections in breast implants: a review with a focus on developing countries”, J Infect Dev Ctries, 2014, 8 (9): 1089-1095.

  3. Araco, A., Gravante, G., Araco, F., Delogu, D., Cervelli, V. y Walgenbach, K., “Infections of breast implants in aesthetic breast augmentations: a single-center review of 3 002 patients”, Aesthetic Plast Surg, 2007, 31 (4): 325-329.

  4. Gabriel, S.E., Woods, J.E., O’Fallon, W.M., Beard, C.M., Kurland, L.T. y Melton, L.J., “Complications leading to surgery after breast implantation”, N Engl J Med, 1997, 336 (10): 677-682.

  5. De Cholnoky, T., “Augmentation mammaplasty. Survey of complications in 10 941 patients by 265 surgeons”, Plas Reconstr Surg, 1970, 45 (6): 573-577.

  6. Alderman, A.K., Wilkins, E.G., Kim, H.M. y Lowery, J.C., “Complications in postmastectomy breast reconstruction: two-year results of the Michigan Breast Reconstruction Outcome Study”, Plast Reconstr Surg, 2002, 109 (7): 2265-2274.

  7. Kjoller, K., Holmich, L.R., Jacobsen, P.H., Friis, S., Fryzek, J., McLaughlin, J.K. et al., “Epidemiological investigation of local complications after cosmetic breast implant surgery in Denmark”, Ann Plastic Surg, 2002, 48 (3): 229- 237.

  8. Reilly, J., Twaddle, S., McIntosh, J. y Kean, L., “An economic analysis of surgical wound infection”, J Hosp Infect, 2001, 49 (4): 245-249.

  9. Bartsich, S., Ascherman, J.A., Whittier, S., Yao, C.A. y Rohde, C., “The breast: a clean-contaminated surgical site”, Aesthet Surg J, 2011, 31 (7): 802-806.

  10. Thornton, J.W., Argenta, L.C., McClatchey, K.D. y Marks, M.W., “Studies on the endogenous flora of the human breast”, Ann Plast Surg, 1988, 20 (1): 39-42.

  11. Brand, K.G., “Infection of mammary prostheses: a survey and the question of prevention”, Ann Plast Surg, 1993, 30 (4): 289-295.

  12. Pittet, B., Montandon, D. y Pittet, D., “Infection in breast implants”, Lancet Infect Dis, 2005, 5 (2): 94-106.

  13. Macadam, S.A., Mehling, B.M., Fanning, A., Dufton, J.A., Kowalewska-Grochowska, K.T., Lennox, P. et al., “Nontuberculous mycobacterial breast implant infections”, Plast Reconstr Surg, 2007, 119 (1): 337-344.

  14. Vinh, D.C., Rendina, A., Turner, R. y Embil, J.M., “Breast implant infection with Mycobacterium fortuitum group: report of case and review”, J Infect, 2006, 52 (3): e63-67.

  15. Pereira, L.H. y Sterodimas, A., “Autologous fat transplantation and delayed silicone implant insertion in a case of Mycobacterium avium breast infection”, Aesthet Plast Surg, 2010, 34 (1): 1-4.

  16. Feldman, E.M., Ellsworth, W., Yuksel, E. y Allen, S., “Mycobacterium abscessus infection after breast augmentation: a case of contaminated implants?”, jpras, 2009, 62 (9): e330-332.

  17. Thibeaut, S., Levy, P.Y., Pelletier, M.L. y Drancourt, M., “Mycobacterium conceptionense infection after breast implant surgery, France”, Emerg Infect Dis, 2010, 16 (7): 1180-1181.

  18. Boettcher, A.K., Bengtson, B.P., Farber, S.T. y Ford, R.D., “Breast infections with atypical mycobacteria following reduction mammaplasty”, Aesthet Plast Surg, 2010, 30 (4): 542-548.

  19. Tian, H.H., Tan, S.M. y Tay, K.H., “Delayed fungal infection following augmentation mammoplasty in an immunocompetent host”, Singapore Med J, 2007, 48 (3): 256-258.

  20. Wright, P.K., Raine, C., Ragbir, M., Macfarlane, S. y O’Donoghue, J., “The semi-permeability of silicone: a saline-filled breast implant with intraluminal and pericapsular Aspergillus flavus”, jpras, 2006, 59 (10): 1118-1121.

  21. Niazi, Z.B., Salzberg, C.A. y Montecalvo, M., “Candida albicans infection of bilateral polyurethane-coated silicone gel breast implants”, Ann Plast Surg, 1996, 37 (1): 91-93.

  22. Zimmerli, W., Waldvogel, F.A., Vaudaux, P. y Nydegger, U.E., “Pathogenesis of foreign body infection: description and characteristics of an animal model”, J Infect Dis, 1982, 146 (4): 487-497.

  23. Zimmerli, W., Lew, P.D. y Waldvogel, F.A., “Pathogenesis of foreign body infection. Evidence for a local granulocyte defect”, J Clin Invest, 1984, 73 (4): 1191-1200.

  24. Vuong, C., Gerke, C., Somerville, G.A., Fischer, E.R. y Otto, M., “Quorum-sensing control of biofilm factors in Staphylococcus epidermidis”, J Infect Dis, 2003, 188 (5): 706-718.

  25. Costerton, J.W., Stewart, P.S. y Greenberg, E.P., “Bacterial biofilms: a common cause of persistent infections”, Science, 1999, 284 (5418): 1318-1322.

  26. Costerton, J.W., Montanaro, L. y Arciola, C.R., “Biofilm in implant infections: its production and regulation”, Int J Artif Organs, 2005, 28 (11): 1062-1068.

  27. Washer, L.L. y Gutowski, K., “Breast implant infections”, Infect Dis Clin North Am, 2012, 26 (1): 111-125.

  28. Cronin, T.D. y Greenberg, R.L., “Our experiences with the silastic gel breast prosthesis”, Plast Reconstr Surg, 1970, 46 (1): 1-7.

  29. Holm, C. y Muhlbauer, W., “Toxic shock syndrome in plastic surgery patients: case report and review of the literature”, Aesthet Plast Surg, 1998, 22 (3): 180-184.

  30. Clegg, H.W., Bertagnoll, P., Hightower, A.W. y Baine, W.B., “Mammaplasty-associated mycobacterial infection: a survey of plastic surgeons”, Plast Reconstr Surg, 1983, 72 (2): 165-1659.

  31. Moyer, K.E. y Potochny, J.D., “Technique for seroma drainage in implant-based breast reconstruction”, jpras, 2012, 65 (12): 1614-1617.

  32. Olsen, M.A., Lefta, M., Dietz, J.R., Brandt, K.E., Aft, R., Matthews, R. et al., “Risk factors for surgical site infection after major breast operation”, J Am Coll Surg, 2008, 207 (3): 326-335.

  33. Wang, F., Koltz, P.F. y Sbitany, H., “Lessons learned from the acs-nsqip Database: has centralized data collection improved immediate breast reconstruction outcomes and safety?”, Plast Reconstr Surg, 2014, 134 (5): 859-868.

  34. Reish, R.G., Damjanovic, B., Austen, W.G. Jr., Winograd, J., Liao, E.C., Cetrulo, C.L. et al., “Infection following implant-based reconstruction in 1952 consecutive breast reconstructions: salvage rates and predictors of success”, Plast Reconstr Surg, 2013, 131 (6): 1223-1230.

  35. Breast analysis 2014. Disponible en: http://www.fda.gov/ MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/ BreastImplants/ucm239995.htm.

  36. Weichman, K.E., Levine, S.M., Wilson, S.C., Choi, M. y Karp, N.S., “Antibiotic selection for the treatment of infectious complications of implant-based breast reconstruction”, Ann Plast Surg, 2013, 71 (2): 140-143.

  37. Feldman, E.M., Kontoyiannis, D.P., Sharabi, S.E., Lee, E., Kaufman, Y. y Heller, L., “Breast implant infections: is cefazolin enough?”, Plast Reconstr Surg, 2010, 126 (3): 779-785.

  38. Laveaux, C., Pauchot, J., Loury, J., Leroy, J. y Tropet, Y., “Acute periprosthetic infection after aesthetic breast augmentation. Report of three cases of implant ‘salvage’. Proposal of a standardized protocol of care”, Annales de Chirurgie Plastique et Esthetique, 2009, 54 (4): 358-364.

  39. Griffith, D.E., Aksamit, T., Brown-Elliott, B.A., Catanzaro, A., Daley, C., Gordin, F. et al., “An official ats/idsa statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases”, Am J Respir Crit Care Med, 2007, 175 (4): 367-416.

  40. Hardwicke, J.T., Bechar, J. y Skillman, J.M., “Are systemic antibiotics indicated in aesthetic breast surgery? A systematic review of the literature”, Plast Reconstr Surg, 2013, 131 (6): 1395-403.

  41. Khan, U.D., “Breast augmentation, antibiotic prophylaxis, and infection: comparative analysis of 1 628 primary augmentation mammoplasties assessing the role and efficacy of antibiotics prophylaxis duration”, Aesthet Plast Surg, 2010, 34 (1): 42-47.

  42. Jones, D.J., Bunn, F. y Bell-Syer, S.V., “Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery”, Cochrane Database Syst Rev, 2014, (3): CD005360.

  43. “Catheter-associated urinary-tract infections”, Lancet, 1978, 2 (8098): 1033-1034.

  44. Barie, P.S., “Guidelines for antimicrobial prophylaxis in surgery: a must-read, must-heed for every surgeon”, Surg Infect (Larchmt), 2013, 14 (1): 5-7.




2020     |     www.medigraphic.com